Economic Evaluation of Nivolumab as a Second-Line Treatment for Advanced Renal Cell Carcinoma From US and Chinese Perspectives

Cancer - United States
doi 10.1002/cncr.30666
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Nivolumab in the Treatment of Advanced Renal Cell Carcinoma

Oncology in Clinical Practice
Oncology
2019English

Re: Nivolumab Versus Everolimus in Advanced Renal-Cell Carcinoma

European Urology
Urology
2016English

Second-Line Treatment for Renal Cell Cancer

British Journal of Cancer
Cancer ResearchOncology
2012English

Pcn190 - Cost-Effectiveness of Nivolumab + Ipilimumab in First-Line Treatment of Advanced or Metastatic Renal Cell Carcinoma in the Netherlands

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Nivolumab in Treatment of Renal Cell Carcinoma During Renal Replacement Therapy

Oncology in Clinical Practice
Oncology
2019English

Lenalidomide as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Exploration of Biomarkers for Treatment Efficacy

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Clinical and Economic Outcomes of Treatment Sequences for Intermediate- To Poor-Risk Advanced Renal Cell Carcinoma

Immunotherapy
OncologyAllergyImmunology
2020English

Pcn136 - A Cost-Effectiveness Analysis of Nivolumab in Combination With Ipilimumab for the Treatment of Advanced Renal Cell Carcinoma in Canada

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

P3.01-86 Treatment Outcomes With Reduced Frequency of Nivolumab Dosing as Second-Line Therapy in Patients With Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy